By Devina Ramsaroop, Steven Loo Yong Kee, Danylo Sirskyj, Calley Hirsch, Elizabeth Csaszar, and Aaron Dulgar Tulloch
CAR T therapy shows great promise for treating hematologic malignancies, and there is a growing need for bioprocess workflow solutions supporting industrial scale up and scale out of these therapies Challenges. Challenges to overcome in the CAR T manufacturing process include lengthy production times (11 - 21 days), product variability associated with open handling steps, and high manufacturing costs Here we examine and evaluate individual CAR T cell unit operations, commercial reagents, and equipment with process closure potential to develop an improved workflow and increase product consistency.
- Identify commercially available reagents that enhance process efficiency
- Identify and evaluate equipment to reduce manual manipulation time
- Integrate automation strategies to reduce open operations